Elevai Labs Subsidiary, Elevai Biosciences, Highlights Past Preclinical Data From 2022 On EL-32 Showing Statistically Significant Increases In Grip Strength, Motor Function And Body Composition In Aged C57BL/6J Mouse Model.
Portfolio Pulse from Benzinga Newsdesk
Elevai Labs' subsidiary, Elevai Biosciences, has highlighted past preclinical data from 2022 on their product EL-32. The data showed statistically significant improvements in grip strength, motor function, and body composition in an aged mouse model.
October 21, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevai Biosciences, a subsidiary of Elevai Labs, has shared positive preclinical results for EL-32, indicating potential benefits in grip strength, motor function, and body composition in aged mice. This could enhance investor confidence in ELAB's research capabilities.
The preclinical data showing significant improvements in key health metrics for aged mice suggests potential for EL-32, which could lead to further development and commercialization. This news is likely to positively impact ELAB's stock as it demonstrates the company's research potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80